Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution
Kleef, R., Nagy, R., Baierl, A., Bacher, V., Bojar, H., McKee, D. L., Moss, R., Thoennissen, N. H., Szász, M., Bakacs, T.
Published in Cancer Immunology, Immunotherapy (01.05.2021)
Published in Cancer Immunology, Immunotherapy (01.05.2021)
Get full text
Journal Article
Kinetics of the NO/NO2 equilibrium reaction over an iron zeolite catalyst
Bacher, V., Perbandt, C., Schwefer, M., Siefert, R., Turek, T.
Published in Applied catalysis. B, Environmental (02.05.2013)
Published in Applied catalysis. B, Environmental (02.05.2013)
Get full text
Journal Article
Complete response of stage IV pancreatic cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia
Kleef, R., Nagy, R., Bohdjalian, A., Bacher, V., Wychera, A., Kekic, S., McKee, D., Bojar, H., Moss, R.
Published in European journal of cancer (1990) (01.03.2019)
Published in European journal of cancer (1990) (01.03.2019)
Get full text
Journal Article
Kinetics of the NO/NO sub(2) equilibrium reaction over an iron zeolite catalyst
Bacher, V, Perbandt, C, Schwefer, M, Siefert, R, Turek, T
Published in Applied catalysis. B, Environmental (01.05.2013)
Published in Applied catalysis. B, Environmental (01.05.2013)
Get full text
Journal Article
Kinetics of the NO/NO2 equilibrium reaction over an iron zeolite catalyst
BACHER, V, PERBANDT, C, SCHWEFER, M, SIEFERT, R, TUREK, T
Published in Applied catalysis. B, Environmental (2013)
Get full text
Published in Applied catalysis. B, Environmental (2013)
Journal Article
P08.01 Low-dose checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavorable immunological profile (MSIlow, PD-L1 under 1%, TMBlow) – A single-institution experience from 2015 to 2020
Kleef, R, Nagy, R, Bacher, V, Bakacs, T, Lausch, T, McKee, D, Moss, R, Bojar, H, Thoennissen, N
Published in Journal for immunotherapy of cancer (01.10.2020)
Published in Journal for immunotherapy of cancer (01.10.2020)
Get full text
Journal Article
PB2092 IMPLEMENTATION AND VALIDATION OF A COLLABORATIVE PLATFORM FOR LONGITUDINAL BIOBANKING OF VIABLE CELLS AND PLASMA IN MYELOID NEOPLASMS
Brodard, J., Jankovic, J., Schnegg‐Kaufmann, A., Hallal, M., Angelillo‐Scherrer, A., Bacher, V. U., Bonadies, N.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study
Bejanyan, Nelli, Zhang, Meijie, Bo-Subait, Khalid, Brunstein, Claudio, Wang, Hailin, Warlick, Erica D., Giralt, Sergio, Nishihori, Taiga, Martino, Rodrigo, Passweg, Jakob, Dias, Ajoy, Copelan, Edward, Hale, Gregory, Gale, Robert Peter, Solh, Melhem, Kharfan-Dabaja, Mohamed A., Diaz, Miguel Angel, Ganguly, Siddhartha, Gore, Steven, Verdonck, Leo F., Hossain, Nasheed M., Kekre, Natasha, Savani, Bipin, Byrne, Michael, Kanakry, Christopher, Cairo, Mitchell S., Ciurea, Stefan, Schouten, Harry C., Bredeson, Christopher, Munker, Reinhold, Lazarus, Hillard, Cahn, Jean-Yves, van Der Poel, Marjolein, Rizzieri, David, Yared, Jean A., Freytes, Cesar, Cerny, Jan, Aljurf, Mahmoud, Palmisiano, Neil D., Pawarode, Attaphol, Bacher, Vera Ulrike, Grunwald, Michael R., Nathan, Sunita, Wirk, Baldeep, Hildebrandt, Gerhard C., Seo, Sachiko, Olsson, Richard F., George, Biju, de Lima, Marcos, Hourigan, Christopher S., Sandmaier, Brenda M., Litzow, Mark, Kebriaei, Partow, Saber, Wael, Weisdorf, Daniel
Published in Transplantation and cellular therapy (01.01.2021)
Published in Transplantation and cellular therapy (01.01.2021)
Get full text
Journal Article
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani, Kamal, Gomez-Arteaga, Alexandra, Madero-Marroquin, Rafael, Zhang, Mei-Jie, Bo-Subait, Khalid, Sanchez, Jonathan, Wang, Hai-Lin, Aljurf, Mahmoud, Assal, Amer, Bacher, Vera Ulrike, Badawy, Sherif M., Bejanyan, Nelli, Bhatt, Vijaya Raj, Bredeson, Christopher, Byrne, Michael, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Ciurea, Stefan Octavian, DeFilipp, Zachariah, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard, Kanakry, Christopher G., Kansagra, Ankit, Khimani, Farhad, Krem, Maxwell, Lazarus, Hillard, Liu, Hongtao, Martino, Rodrigo, Michelis, Fotios V., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Reshef, Ran, Rizzieri, David, Rowe, Jacob M., Savani, Bipin N., Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Hourigan, Christopher, Sandmaier, Brenda, Litzow, Mark, Kebriaei, Partow, Weisdorf, Daniel, Zhang, Yanming, Tallman, Martin S., Saber, Wael
Published in Blood advances (08.02.2022)
Published in Blood advances (08.02.2022)
Get full text
Journal Article